# BioNTech to acquire Novartis GMP manufacturing site in Marburg, Germany

BioNTech signed a share purchase agreement with Novartis to acquire its GMP certified manufacturing facility in Marburg, Germany, to expand COVID-19 vaccine production capacity by up to 750 million doses per year.

- Type: Acquisition
- Announced: 2020-09-01
- Where: Marburg, Germany, Germany
- Jobs: 300
- Status: announced
- Capacity: 750 million doses per year
- Products: COVID-19 vaccine BNT162b2
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [BioNTech](https://endata.com/companies/27269.md) (acquirer)
- [Novartis](https://endata.com/companies/32041.md) (target)

## Sources

- [biontech.com](https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2020/09/biontech-acquire-gmp-manufacturing-site-expand-covid-19-vaccine.html), 2020-09-01: "This acquisition reflects BioNTech's commitment to expand its manufacturing capacity to meet the global demand for a potential COVID-19 vaccine."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.